Repository logo
 
Publication

Seaweed Secondary Metabolites with Beneficial Health Effects : An Overview of Successes in In Vivo Studies and Clinical Trials

2019-12-20Journal article Open access
Simple item page
dc.contributor.authorRosa, Gonçalo P.
dc.contributor.authorTavares, Wilson R.
dc.contributor.authorSousa, Pedro M. C.
dc.contributor.authorPagès, Aida K.
dc.contributor.authorSeca, Ana M. L.
dc.contributor.authorPinto, Diana C. G. A.
dc.date.accessioned2021-03-12T17:51:55Z
dc.date.available2021-03-12T17:51:55Z
dc.date.issued2019-12-20
dc.description.abstractMacroalgae are increasingly viewed as a source of secondary metabolites with great potential for the development of new drugs. In this development, in vitro studies are only the first step in a long process, while in vivo studies and clinical trials are the most revealing stages of the true potential and limitations that a given metabolite may have as a new drug. This literature review aims to give a critical overview of the secondary metabolites that reveal the most interesting results in these two steps. Phlorotannins show great pharmaceutical potential in in vivo models and, among the several examples, the anti-dyslipidemia activity of dieckol must be highlighted because it was more effective than lovastatin in an in vivo model. The IRLIIVLMPILMA tridecapeptide that exhibits an in vivo level of activity similar to the hypotensive clinical drug captopril should still be stressed, as well as griffithsin which showed such stunning results over a variety of animal models and which will probably move onto clinical trials soon. Regarding clinical trials, studies with pure algal metabolites are scarce, limited to those carried out with kahalalide F and fucoxanthin. The majority of clinical trials currently aim to ascertain the effect of algae consumption, as extracts or fractions, on obesity and diabetes.en
dc.description.sponsorshipThis research was funded by project MACBIOBLUE (MAC/1.1b/086), program Interreg MAC 2014–2020 co-financed by DRCT (Azores Regional Government), supporting G.P. Rosa’s grant, as well as by FCT—Fundação para a Ciência e a Tecnologia, the European Union, QREN, FEDER, and COMPETE, through funding the cE3c center (FCT UID/BIA/00329/2013, 2015–2018 and UID/BIA/00329/2019) and the QOPNA research unit (FCT UID/QUI/00062/2019)en
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationRosa, G.P., Tavares, W.R., Sousa, P.M.C., Pagès, A.K., Seca, A.M.L. & Pinto, D.C.G.A. (2020). Seaweeds secondary metabolites with beneficial health effects: an overview of successes in in vivo studies and clinical trials. "Marine Drugs", 18(1), 8. DOI:10.3390/md18010008en
dc.identifier.doi10.3390/md18010008pt_PT
dc.identifier.issn1660-3397
dc.identifier.urihttp://hdl.handle.net/10400.3/5787
dc.identifier.wos000513184600001
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relation.publisherversionhttps://www.mdpi.com/1660-3397/18/1/8pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectSeaweedsen
dc.subjectSecondary Metabolitesen
dc.subjectin vivo Studiesen
dc.subjectClinical Trialsen
dc.subjectHealth Effectsen
dc.subjectDieckolen
dc.subjectEckolen
dc.subjectFucoxanthinen
dc.subjectKahalalide Fpt_PT
dc.titleSeaweed Secondary Metabolites with Beneficial Health Effects : An Overview of Successes in In Vivo Studies and Clinical Trialsen
dc.typejournal article
dspace.entity.typePublication
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/5876/UID%2FBIA%2F00329%2F2013/PT
oaire.citation.conferencePlaceSwitzerlanden
oaire.citation.endPage35pt_PT
oaire.citation.issue(1)pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleMarine Drugsen
oaire.citation.volume18pt_PT
oaire.fundingStream5876
person.familyNameRosa
person.familyNameSeca
person.givenNameGonçalo
person.givenNameAna
person.identifier.ciencia-id4518-FF32-251F
person.identifier.orcid0000-0002-0706-8505
person.identifier.orcid0000-0002-7709-2375
person.identifier.ridE-5475-2013
person.identifier.scopus-author-id6603279232
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication848abdd5-db5c-4194-9b8a-4aada01290ce
relation.isAuthorOfPublication1c6b511a-fd49-4292-a8a2-b738f558eef1
relation.isAuthorOfPublication.latestForDiscovery848abdd5-db5c-4194-9b8a-4aada01290ce
relation.isProjectOfPublication7eec27e2-98c2-484f-a596-8df735e12eb3
relation.isProjectOfPublication.latestForDiscovery7eec27e2-98c2-484f-a596-8df735e12eb3

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
P1632_Seca_2020_MarineDrugs.pdf
Size:
2.88 MB
Format:
Adobe Portable Document Format
Download

Collections

GBA - Artigos em Revistas Internacionais / Articles in International Journals
DCFQE - Artigos em Revistas Internacionais / Articles in International Journals